Management discusses the RLY-2608 data presented at the American Association for Cancer Research (AACR) Annual Meeting on a conference call to be held on April 18 at 1:30 pm. Webcast Link
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on RLAY:
- Relay Therapeutics to Participate in Two Upcoming Investor Conferences
- Relay Therapeutics Plunges on Latest Cancer Data
- Relay Therapeutics says RLY-2608 selectively targets multiple PI3Ka mutations
- Relay Therapeutics Announces Initial Clinical Data Demonstrating that RLY-2608 Selectively Targets Multiple PI3Kα Mutations
- Relay Therapeutics to host conference call